I spoke with neuroscientist Adrian Owen, co-founder and Chief Scientific Officer & Faraz Shafaghi, Chief Product Officer, at neurological testing company Creyos (which rhymes with “chaos”). Their cognitive assessment platform gives a baseline of neurological function and is essentially getting objective data at a point of care. This can now be done as part of…
In this JAMA Health Forum column, KFF’s Larry Levitt examines the criticism that health insurance companies are facing from political leaders, and explores the industry’s role in both causing and addressing some of the health systems’ biggest problems, including rising costs and prior authorization review.
The question is no longer whether shareback matters. It is whether the healthcare ecosystem is willing to prioritize it in practice by recognizing it in policy measurement, monitoring, and enforcement, as well as investing in the technical and governance structures needed to make shareback routine, high-quality, measurable, and reportable. The post Why Quality Shareback is…
Healthcare has solved for the hard part. The science, the surgery, the diagnosis: by global standards, we’re exceptional. What we haven’t solved for is what happens when the patient goes home. The post The Healthcare Industry Has a Last Mile Problem — It Hasn’t Realized It Yet appeared first on MedCity News.
Five technology companies have launched dedicated consumer-facing AI health tools so far in 2026, reflecting though questions about AI’s reliability remain. And a decades-old WHO classification has been misrepresented online to suggest that hormonal birth control pills were recently found to cause cancer.
The Peterson Health Technology Institute (PHTI) recently released a report titled: “Administrative AI: Current Use and Potential Impact.” The report was based on a workshop PHTI convened with senior leaders from health systems, health plans, technology developers, investment firms, and federal agencies in order to discuss how technology and policy can enable AI to reduce…
At the Medicarians Conference, Ricardo Carcas, assistant special agent in charge of the Office of Investigations, discussed cases of fraud in the ACA and how the DOJ is combatting it. The post How the DOJ Is Tackling Fraud in the ACA Marketplace appeared first on MedCity News.
Merck’s HIV drug Idvynso could become a drug choice for patients who need to switch from Gilead Sciences’ Biktarvy for safety or tolerability reasons. The Merck combination drug pairs two molecules that bring different mechanisms of action to suppressing HIV. The post FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral…
Virginia’s General Assembly is set to vote on the Affordable Medicine Act, aiming to extend Medicare drug price negotiations to state plans
Organization’s CEO Aaron Carroll says that despite congressional funding, Agency for Healthcare Research and Quality is not issuing new grants